• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

3-(Pyridin-3-ylamino)propanenitrile: A Promising Compound in Medicinal Chemistry

3-(Pyridin-3-ylamino)propanenitrile (CAS No. 101257-92-5) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound, characterized by its pyridine and nitrile functionalities, has been the subject of numerous studies aimed at elucidating its biological activities and potential as a lead molecule for drug development.

The pyridine moiety in 3-(Pyridin-3-ylamino)propanenitrile is a key structural element that contributes to its pharmacological properties. Pyridine derivatives are well-known for their ability to interact with various biological targets, including enzymes, receptors, and ion channels. The presence of the nitrile group further enhances the compound's versatility by providing a reactive site for chemical modifications, which can be exploited to optimize its pharmacological profile.

Recent research has highlighted the potential of 3-(Pyridin-3-ylamino)propanenitrile as an inhibitor of specific enzymes involved in various disease pathways. For instance, studies have shown that this compound exhibits potent inhibitory activity against certain kinases, which are key enzymes implicated in cancer progression and other proliferative disorders. The ability to selectively target these kinases makes 3-(Pyridin-3-ylamino)propanenitrile a promising candidate for the development of novel anticancer agents.

In addition to its anticancer properties, 3-(Pyridin-3-ylamino)propanenitrile has also been investigated for its potential as an anti-inflammatory agent. Inflammation is a complex biological response that plays a crucial role in various diseases, including arthritis, cardiovascular diseases, and neurodegenerative disorders. Preliminary studies have demonstrated that 3-(Pyridin-3-ylamino)propanenitrile can effectively modulate inflammatory pathways by inhibiting the production of pro-inflammatory cytokines and chemokines.

The pharmacokinetic properties of 3-(Pyridin-3-ylamino)propanenitrile have also been studied to assess its suitability as a drug candidate. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. Its good oral bioavailability and low toxicity profile make it an attractive candidate for further preclinical and clinical evaluation.

To further enhance the therapeutic potential of 3-(Pyridin-3-ylamino)propanenitrile, researchers have explored various chemical modifications to optimize its pharmacological properties. These modifications include the introduction of substituents on the pyridine ring and the nitrile group to improve solubility, stability, and target selectivity. For example, the addition of hydrophilic groups can enhance water solubility, while the introduction of lipophilic groups can improve membrane permeability.

Clinical trials are currently underway to evaluate the safety and efficacy of 3-(Pyridin-3-ylamino)propanenitrile in treating various diseases. Early results from phase I trials have shown promising outcomes, with the compound demonstrating good tolerability and preliminary evidence of therapeutic benefit. These findings have paved the way for more advanced clinical trials to further validate its therapeutic potential.

In conclusion, 3-(Pyridin-3-ylamino)propanenitrile (CAS No. 101257-92-5) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique structural features and favorable pharmacological properties make it an attractive candidate for the development of novel therapeutic agents. Ongoing research and clinical trials are expected to provide further insights into its therapeutic potential and pave the way for its eventual use in clinical practice.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)